Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 24 clinical trials
Safety Tolerability Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to

  • 15 views
  • 01 Jan, 2021
  • 21 locations
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

treated with the combination of copanlisib and rucaparib for as long as the patient does not have clinically significant progressive disease and/or unacceptable toxicity and/or as long as the investigator

liver metastases
measurable disease
apalutamide
androgen suppression
carcinoma
  • 0 views
  • 25 Jan, 2021
  • 1 location
Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL

This is a prospective, multicenter, non-randomized, open-label, phase II study to describe the efficacy of R-CHOP plus copanlisib including a safety run-in phase in order to detect early and

high grade b-cell lymphoma
r-chop chemotherapy
follicular lymphoma
neutrophil count
platelet count
  • 0 views
  • 25 Jan, 2021
  • 6 locations
A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib

hypotheses that REMD-477 is safe and tolerable in patients with severe hyperglycemia on copanlisib and that it decreases the risk of severe hyperglycemia in patients receiving copanlisib for relapsed

  • 0 views
  • 25 Jan, 2021
  • 1 location
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor Copanlisib Given in Combination With the Immunotherapeutic Agents Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Patients with relapsed or refractory follicular or marginal zone lymphoma who have received at least one prior line of therapy will receive Copanlisib IV: day 1, 8, 15 every 28

  • 0 views
  • 25 Jan, 2021
  • 2 locations
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

also being done to find out the highest doses of copanlisib and vemurafenib that, when given in combination, do not cause serious side effects, and whether the study treatment will make radioiodine

measurable disease
BRAF
carcinoma
neutrophil count
absolute neutrophil count
  • 0 views
  • 25 Jan, 2021
  • 7 locations
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

. The PI3K inhibitor Copanlisib has shown high clinical activity in indolent B - cell lymphomas among them MZL. Based on these observations it is the aim of this study to test the toxicity and efficacy

measurable disease
remission
interferon
ct scan
cytopenia
  • 9 views
  • 24 Jan, 2021
  • 23 locations
A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma

The purpose of this study is to test the safety and any good and bad side effects of combining 2 study drugs, copanlisib and ibrutinib. This combination of drugs could shrink your Mantle Cell

  • 8 views
  • 06 Dec, 2020
  • 6 locations
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

This phase I/II trial studies the effects (good and bad) of adding copanlisib to the usual therapy of fulvestrant and abemaciclib in treating patients with hormone receptor positive and HER2

measurable disease
fasting
brain metastases
stage iv breast cancer
neutrophil count
  • 0 views
  • 11 Jan, 2021
  • 10 locations
A Study of a New Drug Combination Copanlisib and Fulvestrant in Advanced Breast Cancer

This phase I/II trial studies the side effects and how well copanlisib works when given together with fulvestrant in treating patients with estrogen receptor positive (ER+) and human epidermal

  • 0 views
  • 25 Jan, 2021
  • 1 location